Publications
600 results found
Thursfield RM, Bush A, Alton EW, et al., 2014, BALF LEVELS OF LL37 CORRELATE WITH BALF CELLULAR AND SOLUBLE MARKERS OF INFLAMMATION IN CHILDREN WITH CYSTIC FIBROSIS, PEDIATRIC PULMONOLOGY, Vol: 49, Pages: 304-304, ISSN: 8755-6863
Griesenbach U, Alton EW, Boyd A, et al., 2014, MOVING TOWARD ASSESSMENT OF LENTIVIRAL VECTOR IN CLINICAL TRIAL, Publisher: WILEY-BLACKWELL, Pages: 297-297, ISSN: 8755-6863
Bayfield KJ, Alton EW, Boyd A, et al., 2014, LUNG FUNCTION OUTCOME MEASURES IN A MULTIDOSE TRIAL OF NON-VIRAL GENE THERAPY IN PATIENTS WITH CF, Publisher: WILEY-BLACKWELL, Pages: 364-365, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 1
Thursfield RM, Bush A, Alton EW, et al., 2014, VITAMIN D DEFICIENCY IS NOT ASSOCIATED WITH <i>PSEUDOMONAS AERUGINOSA</i> OR <i>STAPHYLOCOCCUS AUREUS</i> INFECTION IN CHILDREN WITH CYSTIC FIBROSIS, PEDIATRIC PULMONOLOGY, Vol: 49, Pages: 346-347, ISSN: 8755-6863
Elgmati H, Alton EW, Armstrong DK, et al., 2014, CARDIOPULMONARY EXERCISE TESTING (CPET) AS AN OUTCOME MEASURE IN CYSTIC FIBROSIS CLINICAL TRIAL, Publisher: WILEY-BLACKWELL, Pages: 366-366, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 1
Davies LA, Alton EW, Boyd A, et al., 2014, LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY, Publisher: WILEY-BLACKWELL, Pages: 293-293, ISSN: 8755-6863
Davidson H, Alton E, Cass S, et al., 2014, ASSESSMENT OF THE GENOTOXIC POTENTIAL OF AN F/HN-PSEUDOTYPED LENTIVIRAL VECTOR FOR CF GENE THERAPY, Publisher: WILEY-BLACKWELL, Pages: 301-301, ISSN: 8755-6863
Sumner-Jones SG, Alton EW, Boyd A, et al., 2014, MOLECULAR ANALYSES OF VECTOR DELIVERY AND GENE EXPRESSION IN A MULTIDOSE TRIAL OF NON-VIRAL GENE THERAPY IN PATIENTS WITH CF, Publisher: WILEY-BLACKWELL, Pages: 302-302, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 2
Irving SJ, Davies JC, Alton EWF, et al., 2014, Lung Clearance Index in Primary Ciliary Dyskinesia and Bronchiectasis, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 189, Pages: 1147-1148, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 5
Pringle IA, Alton EW, Boyd CA, et al., 2014, A phase IIb Double-Blind Placebo-Controlled Trial of Non-Viral Gene Transfer for Cystic Fibrosis, 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Publisher: NATURE PUBLISHING GROUP, Pages: S229-S230, ISSN: 1525-0016
Paul-Smith M, Gelinas J-F, Hyde SC, et al., 2014, Alpha-1-antitrypsin gene therapy for lung disease, Annual Conference of the British-Society-for-Gene-and-Cell-Therapy (BSGCT), Publisher: MARY ANN LIEBERT, INC, Pages: A15-A15, ISSN: 1043-0342
Armstrong DK, Cunningham S, Davies JC, et al., 2014, Gene therapy in cystic fibrosis, ARCHIVES OF DISEASE IN CHILDHOOD, Vol: 99, Pages: 465-468, ISSN: 0003-9888
- Author Web Link
- Cite
- Citations: 34
Pringle IA, Alton EW, Connolly MM, et al., 2014, Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy, 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Publisher: NATURE PUBLISHING GROUP, Pages: S141-S141, ISSN: 1525-0016
Alton EWFW, Boyd AC, Cheng SH, et al., 2014, Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung, GENE THERAPY, Vol: 21, Pages: 89-95, ISSN: 0969-7128
- Author Web Link
- Cite
- Citations: 33
Griesenbach U, Featherstone RF, Alton EWFW, 2014, New horizons for cystic fibrosis gene and cell therapy, CYSTIC FIBROSIS, Pages: 150-168, ISSN: 2075-6674
- Author Web Link
- Cite
- Citations: 1
Pabary R, Kumar S, Huang J, et al., 2013, SIFT-MS ANALYSIS AS A NON-INVASIVE DETERMINANT OF PSEUDOMONAS AERUGINOSA INFECTION IN PATIENTS WITH CYSTIC FIBROSIS, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A8-A8, ISSN: 0040-6376
Alton EWFW, Baker A, Baker E, et al., 2013, The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep, BIOMATERIALS, Vol: 34, Pages: 10267-10277, ISSN: 0142-9612
- Author Web Link
- Cite
- Citations: 32
Alton EWFW, Boyd AC, Cheng SH, et al., 2013, A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis, THORAX, Vol: 68, Pages: 1075-1077, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 46
Griesenbach U, Alton EWFW, 2013, Moving forward: cystic fibrosis gene therapy, HUMAN MOLECULAR GENETICS, Vol: 22, Pages: R52-R58, ISSN: 0964-6906
- Author Web Link
- Cite
- Citations: 53
Alton EW, Boyd AC, Cheng SH, et al., 2013, A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF, PEDIATRIC PULMONOLOGY, Vol: 48, Pages: 293-294, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 1
Pabary R, Waller M, Harman K, et al., 2013, INTERPRETATION OF NASAL POTENTIAL DIFFERENCE MEASUREMENTS IN DIFFICULT CASES OF POSSIBLE CYSTIC FIBROSIS AND THE ROLE OF PUBLISHED EQUATIONS, PEDIATRIC PULMONOLOGY, Vol: 48, Pages: 257-257, ISSN: 8755-6863
Pabary R, Huang J, Kumar S, et al., 2013, SIFT-MS ANALYSIS OF EXHALED BREATH AS A NONINVASIVE DETERMINANT OF PSEUDOMONAS AERUGINOSA INFECTION IN CF PATIENTS, PEDIATRIC PULMONOLOGY, Vol: 48, Pages: 295-295, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 2
Irving SJ, Ives A, Davies G, et al., 2013, Lung Clearance Index and High-Resolution Computed Tomography Scores in Primary Ciliary Dyskinesia, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 188, Pages: 545-549, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 63
Calcedo R, Griesenbach U, Dorgan DJ, et al., 2013, Self-Reactive CFTR T Cells in Humans: Implications for Gene Therapy, HUMAN GENE THERAPY CLINICAL DEVELOPMENT, Vol: 24, Pages: 108-115, ISSN: 2324-8637
- Author Web Link
- Cite
- Citations: 7
Horsley AR, Davies JC, Gray RD, et al., 2013, Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation, Thorax, Vol: 68, Pages: 532-539, ISSN: 1468-3296
Background Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well characterised and clinically relevant outcome measures.Aim To evaluate a range of conventional and novel biomarkers of CF lung disease in a multicentre setting as a contributing study in selecting outcome assays for a clinical trial of CFTR gene therapy.Methods A multicentre observational study of adult and paediatric patients with CF (>10 years) treated for a physician-defined exacerbation of CF pulmonary symptoms. Measurements were performed at commencement and immediately after a course of intravenous antibiotics. Disease activity was assessed using 46 assays across five key domains: symptoms, lung physiology, structural changes on CT, pulmonary and systemic inflammatory markers.Results Statistically significant improvements were seen in forced expiratory volume in 1 s (p<0.001, n=32), lung clearance index (p<0.01, n=32), symptoms (p<0.0001, n=37), CT scores for airway wall thickness (p<0.01, n=31), air trapping (p<0.01, n=30) and large mucus plugs (p=0.0001, n=31), serum C-reactive protein (p<0.0001, n=34), serum interleukin-6 (p<0.0001, n=33) and serum calprotectin (p<0.0001, n=31).Discussion We identify the key biomarkers of inflammation, imaging and physiology that alter alongside symptomatic improvement following treatment of an acute CF exacerbation. These data, in parallel with our study of biomarkers in patients with stable CF, provide important guidance in choosing optimal biomarkers for novel therapies. Further, they highlight that such acute therapy predominantly improves large airway parameters and systemic inflammation, but has less effect on airway inflammation.
Alton EW, Davies JC, Griesenbach U, 2013, Foreword: Current & emerging pharmaceutical treatments for cystic fibrosis lung disease, ISBN: 9781780841489
This book contains contributions on cystic fibrosis (CF) lung disease from leading international investigators. In eight chapters, they describe exciting progress in each of their respective fields, from pathogenesis through symptomatic treatments to addressing the basic defect. Each describes an iterative process in the best traditions of science; hypotheses being tested, rejected or improved. All of the authors have made major contributions to the cause of CF research and treatment over many years, and in this book the Editors have encouraged them to speculate and to be controversial where necessary, providing genuine insight through their experience and expertise.
Duff RM, Simmonds NJ, Davies JC, et al., 2013, A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis, EUROPEAN RESPIRATORY JOURNAL, Vol: 41, Pages: 991-993, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 10
Griesenbach U, Alton EWFW, 2013, Expert opinion in biological therapy: update on developments in lung gene transfer, EXPERT OPINION ON BIOLOGICAL THERAPY, Vol: 13, Pages: 345-360, ISSN: 1471-2598
- Author Web Link
- Cite
- Citations: 19
Kernan NG, Alton EWFW, Cullinan P, et al., 2013, Oral contraceptives do not appear to affect cystic fibrosis disease severity, EUROPEAN RESPIRATORY JOURNAL, Vol: 41, Pages: 67-73, ISSN: 0903-1936
- Author Web Link
- Open Access Link
- Cite
- Citations: 20
Thursfield RM, Bush A, Alton EWFW, et al., 2012, AIRWAY INFLAMMATION IS PRESENT BY 4 MONTHS IN CF INFANTS DIAGNOSED ON NEWBORN SCREENING, Winter Meeting of the British-Thoracic-Society 2012, Publisher: BMJ PUBLISHING GROUP, Pages: A40-A41, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 1
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.